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a b s t r a c t
Objectives: To assess the efﬁcacy of tolvaptan in acute heart failure with hyponatremia using
a randomized double-blinded placebo-controlled study design.
Background: Tolvaptan is a selective vasopressin receptor 2 antagonist. There are no pub-
lished clinical trials on the utility of tolvaptan in acute heart failure with hyponatremia in
the Indian population.
Methods: After screening and informed consent, 51 HF patients with hyponatremia were
randomized using computer-generated randomization sequence to receive placebo or 15 mg
of tolvaptan for 5 days along with conventional medical therapy. The patient's perception of
dyspnea using Likert score and the plasma sodium was measured at baseline and for the
next 4 days.
Results: There was a mean improvement in sodium concentration by 5 mEq/L ( p = 0.001) in
patients receiving tolvaptan, whereas no signiﬁcant improvement was seen in the placebo
group (p = 0.33). Signiﬁcant improvement in Likert score was observed in both the groups
(p = 0.001), even though there was no difference between both the groups. Dry mouth and
thirst were the most commonly occurring adverse effects observed in both the groups. There
were no signiﬁcant hemodynamic changes with tolvaptan therapy.
Conclusion: Tolvaptan at a dose of 15 mg is effective in reversing hyponatremia in acute heart
failure and may be a suitable option in these patients.
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* Corresponding author.
E-mail address: melvingeorge2003@gmail.com (M. George).
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier.com/locate/ihjhttp://dx.doi.org/10.1016/j.ihj.2015.07.006
0019-4832/# 2015 Cardiological Society of India. Published by Elsevier, a division of Reed Elsevier India, Pvt. Ltd. All rights reserved.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 1 5 – s 2 1S161. Introduction
Hyponatremia is a condition characterized by plasma sodium
less than 135 mEq/L and is a complication that is seen in over
20% of patients with heart failure.1 When hyponatremia is left
untreated, it can result in severe neurological symptoms, such
as seizures and obtundation.2,3 Hyponatremia has been shown
to be associated with increased rate of rehospitalization,
length of stay, utilization of greater hospital resources,
increased complications, and greater economic burden.4
Studies have also shown that hyponatremia is a critical
predictor of survival in patients with heart failure.5,6 Arginine-
vasopressin (AVP) concentration is disproportionately elevat-
ed in decompensated heart failure and hyponatremia. The
increased AVP is responsible for the impaired free water
clearance in heart failure. One of the mechanisms responsible
for this is the increase in the number of AQ2 water channels in
the collecting duct that promote excess water retention
resulting in hypervolemia and hyponatremia.7 Thus vasopres-
sin plays a central role in the development of hyponatremia in
heart failure. Loop and thiazide diuretics are considered to be
the mainstay therapy for reversal of complications related to
water retention. However, use of such diuretics is known to be
associated with worsening of hyponatremia, renal dysfunc-
tion, and hypotension due to loss of intravascular volume with
sodium depletion.8–10
Tolvaptan, a non-peptide vasopressin type 2 receptor
antagonist, is now available for patients with heart failure
with hyponatremia. Tolvaptan stimulates free water clear-
ance by inhibiting vasopressin-mediated water reabsorption
in the renal collecting ducts.11,12 Studies have been published
on the efﬁcacy and safety of tolvaptan in patients with
heart failure. The EVEREST trial, which included 4133
patients from the American and European population,
showed that tolvaptan when added to standard diuretic
therapy was able to improve most of the signs and symptoms
of heart failure.13 In acute heart failure, tolvaptan at doses of
15–45 mg was able to reverse the signs of ﬂuid overload in
Japanese population.14 The drug was approved in India in
2012 for the treatment of hyponatremia associated with
SIADH or euvolemic or hypervolemic hyponatremia due to
CHF, cirrhosis, or SIADH. Since there are no clinical trials
performed with tolvaptan in the Indian population till date,
we performed this study to evaluate the short-term efﬁcacy
of tolvaptan in patients with acute heart failure and
hyponatremia.
2. Methodology
This study was a randomized placebo-controlled double-
blinded clinical trial that was conducted in the Department of
Cardiology at SRM Medical College Hospital and Research
Centre, Chennai, Tamil Nadu, India between April 2013 and
August 2014. The protocol was approved by the Institute Ethics
Committee of SRM Medical College Hospital and was regis-
tered in the Clinical Trial Registry of India CTRI/2013/05/
003643.2.1. Inclusion criteria
We included patients admitted with a clinical diagnosis of
acute heart failure and concomitant hyponatremia presenting
with dyspnea at rest or minimal exertion with evidence of at
least one of the following features, such as orthopnea,
peripheral edema, elevated JVP, pulmonary rales, or conges-
tion on chest X-ray.
2.2. Exclusion criteria
Patients with systolic blood pressure less than 90 mmHg,
serum sodium greater than 140 mEq/L, and serum creatinine
greater than 3 mg/dl were not included in the study. Patients
with history of acute coronary syndrome in past 4 weeks,
valvular heart disease and terminal illness due to other causes,
pregnant, and nursing women were also excluded from the
study.
All demographic information, such as age, sex, previous
medical history, clinical features, current drug history, and
routine laboratory investigations were recorded. Written
informed consent was taken from all the patients included
in the study. Patients were randomized using a computer-
generated randomization sequence (Random Allocation soft-
ware, version) to receive tolvaptan 15 mg or placebo in a 1:1
ratio for a maximum duration of 5 days. The protocol required
that the study drug/placebo be stopped if the plasma
concentration of sodium exceeded 145 mEq/L, irrespective of
the number of days of therapy. Block randomization was
performed with a block size of 6. Allocation concealment was
maintained using serially numbered opaque sealed envelopes
and was maintained by one of the investigators not involved in
patient recruitment. Background medical therapy was given as
directed by the treating cardiologist. There was no restriction
applied on the dose of diuretic used in the study patients.
2.3. Measurement of end points
The plasma sodium and the patients perception of dyspnea
were assessed before administration of the study drug or
placebo. The patient's perception of dyspnea was assessed
using Likert score. The score was recorded as 3 to +3, with 3
being markedly worse, 2 being moderately worse, 1 mildly
worse, 0 as no change, +1 being mildly better, +2 being
moderately better and +3 being markedly better. Plasma
sodium, Likert score, urine output and adverse events were
recorded daily for 5 days. The adverse events which we mainly
looked for in the study patients were dry mouth, thirst,
polyuria, ventricular extrasystoles, constipation, atrial ﬁbril-
lation, ventricular tachycardia, worsening cardiac failure,
hypotension, hypokalemia, and worsening renal failure.
Patients were assessed at the end of 30 days to assess
cardiovascular outcomes such as death, recurrent hospitali-
zation, and revascularization.
ES and MG were involved in designing the study protocol.
CRM, KA, BK, and ES were involved in recruiting patients. MR,
KA, BK, and AJ were involved in data collection. MG and AJ
performed the statistical analysis. The manuscript was
prepared by AJ and MG and was edited by CRM and ES. All
authors approved the ﬁnal version of the manuscript.
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Data are expressed as mean  SD or median with interquartile
range or percentages. The baseline characteristics of the study
patients were compared using Student's t-test or Pearson's
Chi-squared test. The sodium concentration before and after 5
days of therapy with drug therapy in each group was compared
using paired t test, and the difference between the change in
sodium concentration in tolvaptan and placebo groups was
compared using independent 't' test. The Likert score between
D1 and D5 was compared using Wilcoxon signed rank test. The
BP and heart rate before and after therapy with study drug and
placebo were also compared using paired t test. In patients
who did have data of D4 or D5, the last observation was carriedFig. 1 – Flowchart showinforward (LOCF). A p value of <0.05 was considered statistically
signiﬁcant. Data were analyzed using SPSS v.16.
3. Results
A total of 51 patients with acute decompensated heart failure
were enrolled in the study. Most patients had mild to moderate
hyponatremia. 25 patients were randomized to tolvaptan
15 mg and 26 patients received placebo (Fig. 1). The study drug
was given for a time period of 5 days. Background medical
therapy was given as directed by the treating cardiologist.
There was no restriction applied on the dose of diuretic used in
the study patients.g study recruitment.
Table 1 – Baseline characteristics of study patients.





Age 58.9  12.1 57  12.0 0.71
Male (%) 19(76.0) 17(65.4) 0.40
Diabetes mellitus (%) 14(60.9) 13(50) 0.44
Hypertension (%) 11(44.0) 10(38.5) 0.68
Smoking (%) 3(13.0) 4(16) 0.77
Dyslipidemia (%) 3(13.0) 4(16) 0.77







Previous CABG (%) 3(13.0) 5(19.2) 0.55
CRF (%) 5(21.7) 3(12.0) 0.36
PVD (%) 3(13.0) 0 0.06
Stroke (%) 1(4.5) 2(7.7) 0.65
Previous COPD (%) 1(4.5) 2(7.7) 0.62
BMI (kg/m2) 23.3  3.2 27.4  5.7 0.01
SBP (mmHg) 114.6  16.9 122.4  21.6 0.28
DBP (mmHg) 73.5  6.78 80.1  14.5 0.07




Pedal edema (%) 11(44) 9(34) 0.75
Rales (%) 4(16) 7(26) 0.49
Urea (mg/dl) 49.3  28.1 46.2  38.1 0.74
Creatinine (mg/dl) 1.3  0.56 1.3  0.69 0.88
LVEF (%) 31.9  12.2 29.2  8.7 0.36
Values are expressed as means  SD or frequency with percen-
tages. BMI: body mass index; CABG: coronary artery bypass graft;
COPD: Chronic obstructive pulmonary disease; CRF: chronic renal
failure; DBP: diastolic blood pressure; HF: heart failure; LVEF: left
ventricular ejection fraction; PVD: peripheral vascular disease; SBP:
systolic blood pressure.






ACE inhibitors 9(36.0) 12(46.2) 0.32
Dobutamine 8(32.0) 15(53.8) 0.09
Dopamine 1(4.0) 1(3.8) 0.74
Furosemide 21(84.0) 26(100) 0.05
Digoxin 7(28.0) 10(38.5) 0.31
Trimetazidine 12(48.0) 13(50.0) 0.55
Aspirin 8(32.0) 7(26.9) 0.46
Clopidogrel 12(48.0) 13(50) 0.55
Heparin 10(40.0) 6(23.1) 0.15
Statins 16(64.0) 15(57) 0.43
Ivabradine 2(8.0) 4(15.4) 0.35
Nitrates 15(60.0) 11(42.3) 0.16
Spironolactone 16(64.0) 21(80.8) 0.15
Olmesartan 0 1(3.8) 0.51
Nicorandil 5(20.0) 4(15.4) 0.47
Beta blockers 10(40.0) 9(34.6) 0.62
Amlodopine 4(16.0) 4(15.4) 0.62
Amiodaraone 1(4.0) 1(3.8) 0.74
Verapamil 1(4.0) 0 0.49
Fig. 2 – Change in sodium concentration over 5 days of
therapy in both the study groups.
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Table 1 shows the baseline characteristics of the randomized
patients. No signiﬁcant difference was found in the baseline
characteristics of the patients between the two groups except
the increased frequency of PVD in the tolvaptan group. There
was no difference in drug therapy between the two groups
(Table 2).
3.2. Serum sodium concentration
Among patients in tolvaptan therapy there was a mean
improvement in sodium concentration by 5 mEq/L that was
statistically signiﬁcant ( p = 0.001). There was no improvement
in serum sodium levels among patients in the placebo group
(p = 0.33). The change in sodium concentration between day 5
and day 1 was compared between the two study groups. There
was a signiﬁcant difference in the improvement seen in the
tolvaptan group compared to placebo (Table 3). The progres-
sion of sodium is displayed in Fig. 2.
3.3. Change in Likert score
We also observed mean changes in Likert's score for all
patients in both the groups from day 1 to day 5, as seen inTable 3. There were signiﬁcant changes in both the groups
(p = 0.001). However there was no signiﬁcant difference in the
changes seen in Likert score between the two study groups.
The progression of Likert score over 5 days is displayed in
Fig. 3.
3.4. Adverse effects
There were no serious adverse events attributable to the study
drug. Table 4 shows the frequency of adverse events observed in
both the study groups. Dry mouth and thirst were the most
common adverse effects seen among the study patients.
Patients were followed up for 30 days from the day of admission
to assess major adverse cardiovascular events. A total of four
patients (two in each group) died within 30 days of hospital
admission. Among them, three occurred during the period of
hospitalization. All four deaths were due to refractory LV failure.
There was an increase in the number of recurrent hospitaliza-
tions in the tolvaptan group within 30 days, but this was not
statistically signiﬁcant ( p = 0.55).
Table 3 – Change in sodium concentration and Likert's score among study patients.
Study drug Sodium concentration (mEq/L) Likert score
D1 D5 p value D1 D5 p value
Tolvaptan (n = 25) 128.2  7.72 134.8  4.68 0.001 1.0 (2.0 to 0.8) 1.0 (1.0 to 2.0) 0.001
Placebo (n = 26) 133.0  3.43 133.8  3.09 0.33 2.0 (3.0 to 0.5) 1.5 (1.0 to 2.0) 0.001
D1 refers to measurement performed prior to drug administration on day 1; D5 refers to measurement performed after 5 days of drug therapy.
Likert score is expressed as median with interquartile range.
Fig. 3 – Change in Likert score for dyspnea over 5 days of
therapy in both study groups.
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Tolvaptan showed neither a signiﬁcant reduction in the blood
pressure nor the heart rate over the period of 5 days ( p > 0.05).
Patients in the placebo arm showed a signiﬁcant drop in both
systolic and diastolic BP at the end of 5 days ( p < 0.01) without
any change in heart rate ( p = 0.07).Table 4 – Adverse effects experienced by study patients.









Ventricular extra systole 2(8.0) 3(11.5)
Constipation 8(32.0) 6(23.1)
Hypotension 2(8.0) 0
Worsening RF 2(8.0) 1(3.8)4. Discussion
To the best of our knowledge, this is the ﬁrst randomized
clinical trial on the efﬁcacy of tolvaptan in hyponatremia in
the setting of HF among Indian population. Our study showed
that tolvaptan at a dose of 15 mg given for 5 days reverses the
hyponatremia in patients with acute decompensated HF.
There was a mean increase of sodium by 6.7 mEq/L at the end
of 5 days of tolvaptan therapy. The ﬁndings of our study are
consistent with other published studies. A study by Gheor-
giade et al. had also shown that patients receiving tolvaptan
in different doses ranging from 30 to 60 mg had a mean
increase in sodium by 4 mEq/L within 24 h of therapy.15 In our
study, the mean change seen after 24 h of tolvaptan 15 mg
therapy was 3.31 mEq/L. Kinugawa et al. found that in
patients with baseline sodium <135 mEq/L, tolvaptan was
able to signiﬁcantly increase the plasma sodium concentra-
tion, a ﬁnding that was not seen in those with baseline sodium
>135 mEq/L.16 A maximal increase by 15 mEq/L was observed
among patients with ADHF at the end of 7 days in an
observational study performed in 40 patients.11 Although it
can be hypothesized that a higher dose of tolvaptan could
have led to greater increase in sodium levels, earlier studies
have not demonstrated a dose-dependent rise in sodium
levels.15 This ﬁnding is intriguing considering the fact that
dose-dependent aquaretic effects have been observed in
studies performed on healthy volunteers.17Nevertheless, this
is a beneﬁcial effect to avoid the development of hyperna-
tremia.
Patients who received tolvaptan did have an improvement
in dyspnea as assessed by Likert score over 5 days, but this
was not signiﬁcantly different from that observed in the
placebo. In contrast, a post hoc analysis, conducted by Pang
et al. in his study, observed that majority of patients in the
study had an improvement in dyspnea at all time points
relative to hospital admission, with a signiﬁcant statistically
higher rate in tolvaptan group compared with placebo group
in addition to standard medical therapies.18 In a study
conducted by Hauptman et al., more patients with hypona-
tremia receiving tolvaptan had a better improvement of
dyspnea compared to placebo. In patients with normona-
tremia, there were a lesser number of cases that had dyspnea
improvement in tolvaptan compared to placebo.19 As most of
the patients in our study had mild to moderate hyponatremia,
it could possibly explain the lack of substantial beneﬁt of
tolvaptan over placebo in dyspnea relief. In addition our study
was not powered sufﬁciently to demonstrate the improve-
ment in dyspnea.
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rate or blood pressure during the study period and these
ﬁndings are in line with earlier published reports on the lack of
hemodynamic changes observed with the drug. In a double-
blinded study investigating the effects of three doses of
tolvaptan and placebo in patients with CHF by Gheorgiade
et al., no vital changes in heart rate or systolic or diastolic blood
pressure, in supine or standing position, were observed in the
tolvaptan groups during the study.15 In a phase III, random-
ized, double-blind, placebo-controlled study (QUEST Study)
conducted by Matsujaki et al., there was a minimal difference
in blood pressure or heart rate between the tolvaptan and the
placebo groups.12 Udelson et al. in his multicenter, random-
ized, double-blinded, placebo-controlled study of tolvaptan
monotherapy compared to furosemide and the combination of
tolvaptan and furosemide in patients with heart failure and
systolic dysfunction found no signiﬁcant changes in blood
pressure or heart rate after administration of tolvaptan or
furosemide or their combination.20
Dry mouth and thirst were the major adverse effects
observed with tolvaptan in the present study. Although there
were two deaths in the tolvaptan group, these were attribut-
able to the recalcitrant AHF in these patients, rather than any
effect of the study medication. One patient in our study
discontinued the medication after the third day due to
persistent nausea. In the study conducted by Gheorgiade
et al., in which dry mouth, thirst, and polyuria, including
urinary frequency, were higher in the tolvaptan-treated
patients and only two patients in the 60-mg tolvaptan group
discontinued the drug on account of polyuria.15 Most fre-
quently reported adverse drug reactions observed in the study
conducted by Inomata et al. were thirst, increased blood urea,
and pollakiuria.9 Similarly no serious adverse effects were
observed in the study by Matsujaki et al.14 The small sample
size and the short duration of drug administration precluded
us from observing other adverse effects as seen in earlier
studies.
5. Limitations
Although we were able to demonstrate the therapeutic
potential of tolvaptan in this clinical trial, the study had
certain limitations. As this was a single-center study, we were
able to recruit only 51 eligible patients during the study period,
who met the inclusion-exclusion criteria. Most of the patients
in our study had only mild to moderate hyponatremia. For
logistic reasons, we could not assess the body weight of the
patients, an end point which has been used in some of the
earlier studies to measure the drug effect.
6. Conclusion
Tolvaptan when given at a dose of 15 mg/day is effective in
reversing hyponatremia when given over a period of 5 days.
The drug was well tolerated with increased thirst and dry
mouth being the most common adverse effects. Thus
tolvaptan may be safely used to treat hyponatremia in the
setting of acute decompensated heart failure.Conﬂict of interest
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